Related Experiment Video

Updated: Aug 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Low-density lipoprotein-lowering medication and platelet function

Patrizia Ferroni1, Stefania Basili, Francesca Santilli

  • 1Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele, Rome, Italy.

Pathophysiology of Haemostasis and Thrombosis
|August 1, 2006
PubMed

Insights

High low-density lipoprotein cholesterol (LDL-C) impacts atherosclerosis and platelet function. LDL-C-lowering drugs show varied effects on platelet activity, with statins and fibrates demonstrating anti-thrombotic potential.

Area of Science:

  • Cardiovascular Science
  • Pharmacology

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerosis, cardiovascular morbidity, and mortality.
  • LDL-C influences platelet function through various mechanisms, potentially enhancing thrombotic events.

Purpose of the Study:

  • To review the impact of LDL-C on platelet function.
  • To evaluate the effects of different LDL-C-lowering agents on platelet activity and their implications for vascular protection.

Main Methods:

  • Literature review of studies investigating LDL-C, platelet function, and lipid-lowering therapies.
  • Analysis of mechanisms by which LDL-C and its reduction affect platelet aggregation and sensitivity.

Main Results:

  • Increased or modified LDL enhances platelet function and agonist sensitivity.
  • Statins exhibit anti-platelet activity, contributing to their anti-thrombotic effects.
  • Fibrates inhibit platelet function, while bile acid sequestrants do not appear to affect it.

Conclusions:

  • LDL-C-lowering agents have diverse effects on platelet function.
  • Statins and fibrates show potential in vascular protection through anti-platelet mechanisms.
  • Further research is needed to fully understand the therapeutic benefits of these agents in plaque stabilization and thrombosis.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...